in 2020, a phase III clinical trial recruited 202 patients with FLT3-ITD AML across seven hospitals in China and randomized patients at post-transplant day 30 to either placebo or sorafenib 400 mg twice per day until post-transplant day 180. Here, FLT3 is linked to acute myeloid leukemia.